Hemostemix Inc. (CVE:HEM – Get Free Report) fell 19.4% on Thursday . The stock traded as low as C$0.14 and last traded at C$0.15. 519,694 shares changed hands during trading, a decline of 1% from the average session volume of 526,987 shares. The stock had previously closed at C$0.18.
Hemostemix Stock Performance
The firm has a 50 day moving average of C$0.20 and a two-hundred day moving average of C$0.12. The company has a debt-to-equity ratio of -55.07, a current ratio of 0.04 and a quick ratio of 0.48. The stock has a market cap of C$25.50 million, a PE ratio of -5.10 and a beta of 0.20.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
See Also
- Five stocks we like better than Hemostemix
- Business Services Stocks Investing
- 3 Stocks Poised to Thrive as NVIDIA Dominates the AI Boom
- 2 Rising CRM Platform Stocks That Can Surge Higher in 2025
- MercadoLibre: High-Growth EM Stock With 100% Upside Potential
- Using the MarketBeat Dividend Tax Calculator
- As the Magnificent 7 Stalls, These 3 Stocks Are Gaining Momentum
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
